3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
OTHER
13
NIH
9
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Breast
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Neoplasms
5
Uterine Cervical Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Dysplasia
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Skin Neoplasms
1
Sarcoma, Endometrial Stromal
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Leiomyosarcoma
1
Leiomyoma
1
Head and Neck Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
Biopsy
×
Clear all
NCT07327489
2026-01-08
ELEPHAS-05
Elephas
Recruiting
2,000 enrolled
NCT06182306
2024-04-03
PEAR-MET
Ourotech, Inc.
Recruiting
30 enrolled